MedWatch

Analyst believes in continued progress for Ambu

When Ambu reveals its Q2 financial report on Wednesday morning, Sydbank analyst Søren Løntoft Hansen expects to see continued strong growth for single-use endoscopes.

Photo: Sydbank/PR

Ambu has had wind in its sails when it comes to the sale of single-use endoscopes, which may very well continue into the second quarter of the financial year 2020/2021.

However, the growth for the company's visualization business leg is hard to compare to the second quarter last year, Søren Løntoft Hansen, senior equity analyst at Sydbank warns.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs